证券代码： 000931 证券简称：中关村 北京中关村科技发展（控股）股份有限公司 投资者关系活动记录表 编号：2019-002 | --- | --- | --- | --- | |-----------------------------|------------------------------|---------------------------------------------------|------------------------------------------------------------| | | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 □媒体采访 | | | 类别 | | □业绩说明会 □新闻发布会 □路演活动 | | | | □ 现场参观 □其他 | | | | 参与单位名称及 | | | 广证恒生 唐爱金、国泰君安证券、怀新投资 李东平、珠海市怀远 | | 人员姓名 | 基金 陈磊、中信建投证券 俞冰 | | | | 时间 | 2019 年 7 月 25 | 日上午 9:30 | | | 地点 | 电话会议 | | | | | | | ...

证券代码： 000931 证券简称：中关村 北京中关村科技发展（控股）股份有限公司 投资者关系活动记录表 编号：2019-003 | --- | --- | --- | --- | |----------------|----------------------|------------------------------------|-------------------------------------| | | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 □媒体采访 | | | 类别 | | □业绩说明会 □新闻发布会 □路演活动 | | | | □ 现场参观 □其他 | | | | 参与单位名称及 | 现场参会（ 33 | 名）： 北京创新产业投资公司 | 何京伟； 国泰君安 | | 人员姓名 | 证券 张帅、孙明达； | 中信建投证券 | 阳明春、周宜鸿； 中信证券 刘 | | | 泽； 财通证券 | 纪文凯； 天风证券 | 贾帅； 东兴证券 张敏； 中 | | | 金公司 | 张轶捷、刘黎鑫； 东海证券 | 王辉； 华林证券 马乐； 中航 | | | 证券 齐仝； | ...

证券代码：000931 证券简称：中关村 编号：2021-001 北京中关村科技发展（控股）股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------------|-----------------------------------------------|-------------------------------------------------------|-----------------------| | 投资者关系活动 \n类别 | √ 特定对象调研 \n□ 业绩说明会 \n□ 现场参观 □ | □ 分析师会议 □ \n □ 新闻发布会 □ \n其他 | 媒体采访 \n路演活动 | | 参与单位名称及 | 华鑫证券 | | | | 人员姓名 | 1. 郑木清，总裁助理； | | | | | 2. | 傅子恒，私募基金研究中心总经理； | | | | 3. | 周韬雄，实战研究员、投资经理； | | | | 4. | 蔺钰尧，实战研究员、投资经理。 | | | 时间 | 2021 年 9 月 15 | 日上午 10: ...

证券代码： 000931 证券简称：中关村 编号：2021-002 | --- | --- | --- | --- | |-----------------------------|----------------------------------|------------------------------------------|------------------------------------------| | | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | □ 媒体采访 | | 类别 | □ 业绩说明会 □ | 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | | √ 其他（参加 2021 | | 年北京辖区上市公司投资者集体接待日活动） | | 参与单位名称及 | 投资者线上参与 | | | | 人员姓名 | | | | | 时间 | 2021 年 9 月 23 日下午 | 15:00-17:00 | | | 地点 | 北京市朝阳区霄云路 | 26 号鹏润酒店会议室及线上直播 | | | 上市公司接待人 员姓名 | 中关村科技董事兼总裁 ...

Financial Performance - The company's operating revenue for Q3 2022 was CNY 524,657,605.30, representing a 3.02% increase year-over-year[5] - Net profit attributable to shareholders for Q3 2022 was CNY 9,393,163.75, a significant increase of 114.41% compared to the same period last year[5] - The basic earnings per share for Q3 2022 was CNY 0.0125, reflecting a 114.41% increase year-over-year[5] - Total operating revenue for the current period reached ¥1,538,628,824.11, an increase of 5.3% compared to ¥1,460,919,478.78 in the previous period[53] - Net profit for the current period was ¥28,110,703.15, a significant recovery from a net loss of ¥32,739,792.19 in the previous period[54] - The company reported a basic and diluted earnings per share of ¥0.0175, compared to a loss per share of ¥0.0663 in the previous period[55] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,656,113,459.21, a decrease of 1.11% from the end of the previous year[5] - The company's current assets totaled CNY 1,593,821,119.33, showing a slight increase from CNY 1,582,962,234.60 at the beginning of the year[48] - The total liabilities decreased to CNY 1,814,524,799.17 from CNY 1,883,729,548.00[50] - The company's cash and cash equivalents were CNY 148,119,672.15, down from CNY 170,199,518.79 at the beginning of the year[48] - Short-term borrowings rose to CNY 490,000,000.00 from CNY 453,152,290.00, reflecting an increase of about 8.1%[50] - The company's long-term borrowings increased significantly to CNY 193,500,000.00 from CNY 57,500,000.00, marking an increase of approximately 236.5%[50] Research and Development - Research and development expenses for the period amounted to CNY 80,754,900, marking an 82.05% increase compared to the previous year[10] - Research and development expenses increased to ¥80,754,864.50 from ¥44,358,033.15, indicating a focus on innovation[53] Shareholder Information - The total number of common shareholders at the end of the reporting period is 76,643[15] - The largest shareholder, Gome Holdings Group, holds 27.78% of shares, totaling 209,213,228 shares, with 124,101,400 shares pledged[15] - Gome Electrical Appliances Company, the second-largest shareholder, holds 7.37% of shares, totaling 55,500,355 shares, with 50,000,000 shares pledged[15] - Gome Holdings has pledged a total of 111,601,400 shares, accounting for 53.34% of its holdings and 14.81% of the company's total share capital[21] Tax and Refunds - The company received tax refunds amounting to CNY 20,385,200, a substantial increase of 1,187.25% year-over-year, due to VAT refund policies[12] - The company reported a significant decrease in tax expenses, down to ¥24,615,358.29 from ¥47,683,071.97 in the previous period[53] Corporate Governance - The company has completed the election of the eighth board of directors and the eighth supervisory board, with key appointments including Xu Zhongmin as chairman and Hou Zhanjun as president[17] - The independent director's allowance has been adjusted from 90,000 RMB to 120,000 RMB per year to enhance their decision-making support and supervision[18] - The company has increased its information disclosure media to include Shanghai Securities Journal, enhancing communication with the market[19] Strategic Partnerships - The company signed a cooperation framework agreement with Beijing Youxun Medical Laboratory to leverage resources in the healthcare sector[22] - The strategic cooperation agreement between the parties aims to leverage Party A's operational advantages and Party B's expertise in COVID-19 testing, with revenue sharing based on the new nucleic acid testing services[23] Legal and Compliance - The third quarter report has not been audited[58] - The announcement was made by the Board of Directors on October 27, 2022[59]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,013,971,218.81, representing a 6.55% increase compared to ¥951,617,787.16 in the same period last year[24]. - The net profit attributable to shareholders decreased by 75.28% to ¥3,768,010.26 from ¥15,241,899.13 year-on-year[24]. - The net cash flow from operating activities turned negative at -¥85,530,101.10, a decline of 255.73% compared to ¥54,922,062.53 in the previous year[24]. - Basic earnings per share dropped by 75.25% to ¥0.0050 from ¥0.0202 in the same period last year[24]. - Total assets at the end of the reporting period were ¥3,670,824,211.91, a slight decrease of 0.71% from ¥3,697,207,504.90 at the end of the previous year[24]. - The company's weighted average return on equity was 0.24%, down from 0.89% in the previous year[24]. - The company reported non-recurring gains and losses totaling ¥3,335,174.78 for the period[28]. - The net profit after deducting non-recurring gains and losses was ¥432,835.48, a decrease of 96.03% from ¥10,904,878.35 in the same period last year[24]. Business Segments and Products - The company's main business segments include biopharmaceuticals, personal care products, elderly care services, and other businesses[32]. - Key biopharmaceutical products in the registration process include Zhimu Saponin BⅡ and capsules, currently in Phase I clinical trials, and Benidipine hydrochloride, which has completed supplementary research and is under CDE review[33]. - The company has several major pharmaceutical products, including Bisoprolol fumarate tablets for hypertension and coronary heart disease, which is included in the 2021 National Medical Insurance Directory[34]. - The company has not had any new entries or exits from the National Basic Medical Insurance Drug List during the reporting period[34]. - The company has obtained several invention and utility model patents, including a toothpaste for preventing oral ulcers and a preparation method for a coated tablet containing acetaminophen and tramadol[36]. - The elderly care services include centralized elderly care, home-based elderly care, health management, health consulting, and traditional Chinese and Western medical services[38]. - The company is involved in the sales of biological products through its subsidiary, which includes recombinant human basic fibroblast growth factor and bifidobacterium quadruple live bacteria tablets[35]. - The company has a diverse product portfolio, with a focus on both traditional Chinese medicine and chemical pharmaceuticals[32]. Research and Development - The company invested over 36 million yuan in R&D for biopharmaceutical projects during the reporting period[53]. - The R&D investment surged to CNY 61,828,692.37, marking a significant increase of 196.62% from CNY 20,844,631.40 in the previous year[70]. - The company has established three R&D centers in Beijing, Weihai, and Jiamusi, focusing on independent and collaborative research and development, leading to effective outcomes in new product development and patent registration[40]. - The company is actively engaged in research and development of new technologies to drive innovation in its product offerings[98]. Market Strategy and Expansion - The company aims to enhance its brand influence and market penetration through targeted marketing strategies and a professional team dedicated to market promotion and access[42]. - The pharmaceutical industry is experiencing rapid growth due to increasing healthcare demands driven by rising living standards and an aging population, presenting new opportunities for the company[46]. - The company plans to focus on innovation and expand its product lines, particularly in cardiovascular, oral, digestive, and gynecological fields, while exploring new biopharmaceutical areas[49]. - The company is actively pursuing a business transformation towards biopharmaceuticals, aiming to create multiple business clusters and enhance its market position[49]. - The company is leveraging the "Internet+" model to explore innovative opportunities in healthcare and elderly care, aligning with trends in consumption upgrades and population aging[49]. Financial Management and Risks - The company has established a risk prediction mechanism to monitor its overall financial status in real-time and strengthen cash flow management[113]. - The company is facing external risks including macroeconomic and policy changes, and has implemented a mechanism for information collection and analysis to respond effectively[117]. - The company is enhancing its internal control and audit processes to mitigate risks and ensure compliance with management requirements[61]. Environmental Responsibility - Beijing Huasu Pharmaceutical achieved all pollutant emissions within standards for the first half of 2022, including waste gas, waste water, and solid waste management[136]. - The company has established a complete set of pollution prevention facilities, with the wastewater treatment plant operating effectively since its establishment in 2008[130]. - The company’s pollution control measures include low-nitrogen combustion technology, significantly reducing NOx and SO2 emissions[136]. - The wastewater treatment facilities at both the Liangxiang production base and Cangzhou branch have been constructed to control wastewater pollutants effectively[136]. Legal Matters - The company is currently involved in a legal dispute regarding a debt of 6 million yuan, with an additional interest of 410,000 yuan, totaling 6.41 million yuan claimed from Zhongyu Company[165]. - The company has a pending claim against Blue Ocean Company for a compensation amount of approximately 39.71 million yuan, which is currently under execution[165]. - The company has reported a total of 25.72 million yuan in compensation claims against Huadian Company, with ongoing execution procedures[166]. - The company is actively managing its legal claims and recoveries, which may influence its financial stability and operational strategies moving forward[166]. Corporate Governance - The company completed the election of the eighth board of directors and the eighth supervisory board, appointing senior management and adjusting independent director allowances[198]. - The independent director allowance was adjusted from pre-tax CNY 90,000 per year to pre-tax CNY 120,000 per year to enhance their decision-making support and supervision[199]. - The company appointed Hou Zhanzjun as the president and several vice presidents, including Li Bin, Wang Xihong, and Che Dehui[198].

Financial Performance - The company's operating revenue for 2021 was ¥1,955,834,389.32, representing a 9.29% increase compared to ¥1,789,615,900.58 in 2020[21]. - The net profit attributable to shareholders of the listed company was -¥113,928,031.24, a decrease of 547.94% from ¥25,433,767.67 in 2020[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥120,401,587.84, a decline of 902.91% compared to ¥14,995,571.24 in 2020[21]. - The company's operating income for 2021 was CNY 1,955,834,389.32, an increase of 9.27% compared to CNY 1,789,615,900.58 in 2020[22]. - The net cash flow from operating activities was CNY 263,413,088.30, representing a growth of 31.57% from CNY 200,200,020.26 in the previous year[22]. - The basic and diluted earnings per share were both -CNY 0.1513, a decrease of 547.63% compared to CNY 0.0338 in 2020[22]. - The total assets at the end of 2021 were CNY 3,697,207,504.90, reflecting a 7.01% increase from CNY 3,455,089,205.24 at the end of 2020[22]. - The net assets attributable to shareholders decreased by 6.71% to CNY 1,585,469,489.44 from CNY 1,699,471,784.03 in 2020[22]. - The company reported a negative net profit attributable to shareholders for the first quarter of 2021 at -CNY 6,616,555.53, and for the third quarter, it was -CNY 65,197,855.35[26]. - Non-operating income for 2021 amounted to CNY 6,473,556.60, down from CNY 10,438,196.43 in 2020[27]. Business Strategy and Operations - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[7]. - The company has not reported any changes in its main business since its listing[20]. - The company is subject to various market risks that may affect its future operational plans and objectives[6]. - The company has established three R&D centers and four production bases, enhancing its market position in the pharmaceutical and health products sector[33]. - The company’s brand "Huasu" has been recognized as a nationally famous trademark, indicating strong brand recognition in the market[33]. - The company is positioned to benefit from the growing demand in the healthcare sector, particularly in oral care and aging population services[31][32]. - The company has established a business model focused on oral healthcare, chain pharmacies, and e-commerce, gaining significant industry recognition[34]. - The company has developed a five-in-one elderly care ecosystem, including medical, health, nursing, entertainment, and rehabilitation services, since launching its elderly care business in 2017[34]. - The company’s elderly care services encompass centralized and home-based care, health management, and traditional Chinese medicine services[40]. - The company is currently in the registration process for several drugs, including "Zhi Mu Zao Gan BⅡ" for vascular dementia and "Lian Fen Bian Zuo" for superficial fungal infections[37]. Research and Development - The company has established three R&D centers in Beijing, Shandong, and Heilongjiang, focusing on independent and collaborative research, resulting in effective development of new and existing products[42]. - The company’s R&D expenses surged by 100.38% to CNY 118,713,590.74, primarily due to increased investment in biopharmaceutical development[79]. - R&D investment increased by 101.48% to ¥140,053,660.69 in 2021, accounting for 7.16% of operating revenue, up from 3.88% in 2020[83]. - The number of R&D personnel rose to 255, representing 21.30% of the total workforce, an increase of 10.87% from the previous year[83]. - The company is conducting pilot research for Acetaminophen Oxycodone Tablets, which will meet market demand for analgesics[81]. Market and Sales Performance - The company's pharmaceutical and health products business generated 1.361 billion yuan, accounting for nearly 70% of total revenue[56]. - The sales volume of the main product, Bisoprolol Fumarate Tablets (brand name: "Bosu"), increased by approximately 17.50% year-on-year[57]. - The strategic product, Benidipine Hydrochloride Tablets (registered trademark: "Yuan Zhi"), saw a revenue growth of nearly 26.20% year-on-year[57]. - The biopharmaceutical segment generated ¥1,355,917,691.91, accounting for 69.33% of total revenue, with a slight increase of 0.27% from the previous year[69]. - The healthcare segment experienced a significant decline, with revenue dropping 87.60% to CNY 51,320,030.64 from CNY 96,278,771.47[71]. Financial Management and Governance - The financial report for the year has been audited by Da Hua Certified Public Accountants, which issued a standard unqualified opinion[5]. - The company has not made any adjustments or restatements to previous years' accounting data[21]. - The company has established a fair and transparent performance evaluation system for directors, supervisors, and managers, linking their compensation to company performance[150]. - The company ensures that all shareholders, especially minority shareholders, have equal rights and can fully exercise their rights during shareholder meetings[145]. - The company has implemented a management system for related party transactions to ensure fairness and transparency[145]. Future Outlook - The company expects to achieve a revenue of 2.175 billion yuan in 2022, with a net profit of -33 million yuan, and a net profit attributable to shareholders of -38 million yuan[128]. - The company plans to enhance sales efficiency and performance by leveraging organizational changes and resource optimization in its core pharmaceutical business[128]. - The company intends to shift its focus in the elderly care business from scale expansion to refined and specialized management, enhancing value-added services and profitability[131]. - The company is actively exploring innovative models in healthcare and elderly care through "Internet+" strategies to adapt to consumer upgrades and aging population trends[48]. - The company is exploring new strategies for market expansion and product innovation in the healthcare sector[126]. Risks and Challenges - The company faces risks from external environments, production management, cash flow, product quality, compliance, competition, drug price reductions, and the ongoing impact of the COVID-19 pandemic[134][135][136][140][141]. - The overall economic environment remains uncertain due to the ongoing impact of the COVID-19 pandemic[125]. Corporate Governance - The company maintains independent operations and decision-making capabilities, ensuring no interference from controlling shareholders[146]. - The company has established specialized committees within the board to oversee major matters and ensure effective governance[147]. - The company has commitments from its controlling shareholder to avoid engaging in competitive construction and real estate development businesses[156].

Financial Performance - The company's operating revenue for Q1 2022 was ¥488,182,089.45, representing a 16.71% increase compared to ¥418,291,194.67 in the same period last year[3] - The net profit attributable to shareholders was a loss of ¥6,514,995.06, a slight improvement of 1.53% from a loss of ¥6,616,555.53 in the previous year[3] - The company reported a net loss of ¥805,784,307.28 in retained earnings, compared to a loss of ¥799,269,312.22 at the beginning of the year[23] - The net profit for Q1 2022 was -3,674,526.13 CNY, compared to -510,999.49 CNY in Q1 2021, indicating a significant increase in losses[26] - Operating profit for Q1 2022 was 5,293,768.26 CNY, up from 3,405,706.12 CNY in the same period last year, reflecting a growth of approximately 55.5%[26] - Total revenue from operating activities was 463,482,739.34 CNY, a decrease from 485,233,131.17 CNY in Q1 2021, representing a decline of about 4.9%[29] - The company reported a total comprehensive income of -3,674,526.13 CNY for Q1 2022, compared to -510,999.49 CNY in Q1 2021[27] - Basic and diluted earnings per share for Q1 2022 were both -0.0087 CNY, slightly improved from -0.0088 CNY in Q1 2021[28] Cash Flow and Assets - The net cash flow from operating activities was negative at ¥90,384,953.98, a significant decline of 438.92% compared to a positive cash flow of ¥26,668,686.45 in the same period last year[3] - The company's cash and cash equivalents at the end of the first quarter stood at ¥176,975,230.43, compared to ¥170,199,518.79 at the beginning of the year[20] - Cash and cash equivalents at the end of Q1 2022 totaled 172,300,351.14 CNY, a slight decrease from 174,990,843.48 CNY at the end of Q1 2021[30] - The company experienced a net cash inflow from financing activities of 125,312,756.37 CNY, compared to a net outflow of -29,410,972.92 CNY in the previous year[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,698,418,492.16, a marginal increase of 0.03% from ¥3,697,207,504.90 at the end of the previous year[3] - The company’s total liabilities increased to ¥1,888,615,061.40 from ¥1,883,729,548.00, reflecting a marginal rise of 0.1%[22] - The company’s non-current liabilities rose to ¥606,772,731.10 from ¥471,565,275.39, marking an increase of 28.6%[22] - Accounts receivable decreased to ¥816,254,936.89 from ¥919,244,678.57, indicating a reduction of approximately 11.2%[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 80,595[12] - Gome Holdings Group Co., Ltd. holds 27.78% of shares, amounting to 209,213,228 shares, with 94,101,400 shares pledged[12] - Gome Electrical Appliances Co., Ltd. holds 7.37% of shares, totaling 55,500,355 shares[12] - Beijing Tianxin Wealth Investment Management Co., Ltd. holds 3.06% of shares, equating to 23,029,108 shares[12] Management and Governance - The company appointed new senior management, including Hou Zhanzun as President and Li Bin as Vice President[15] - The independent director's remuneration has been adjusted from 90,000 RMB to 120,000 RMB per year[15] Research and Development - Research and development expenses increased by 212.94% to ¥2,709.15 million, driven by investments from the subsidiary Huasu Biotechnology (Beijing) Co., Ltd.[9] - Research and development expenses surged to ¥27,091,526.55, a significant increase of 212.5% compared to ¥8,657,015.74 in the previous year[24] Product Development and Market Position - The company’s subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., received approval for its hydromorphone raw material and injection from the CDE[17] - The hydromorphone injection has been granted a drug registration certificate, enhancing the company's product line and market competitiveness[17] - The company received a notice of acceptance from the National Medical Products Administration for the consistency evaluation of its Tramadol and Acetaminophen tablets, which is expected to enhance market competitiveness[19] - The company’s subsidiary, Beijing Jiujia Taihe Traditional Chinese Medicine Hospital, has been included in the basic medical insurance designated medical institutions in Beijing[18] - This inclusion aligns with the company's strategic direction to create a comprehensive elderly care service system[18] Financial Expenses - The company experienced a 54.42% rise in financial expenses to ¥1,511.38 million, primarily due to adjustments in lease liabilities by a subsidiary[9] - Long-term borrowings rose by 207.39% to ¥17,674.65 million due to new loans obtained by the subsidiary Beijing Zhongguancun Sihuan Pharmaceutical Development Co., Ltd.[9] - The company reported a significant increase in accounts receivable financing, up 106.82% to ¥13,889.37 million, attributed to increased bill receipts from subsidiaries[9] Non-Operating Income - The total non-operating income for the period was ¥1,650,701.97, which includes government subsidies and other income[6]

Financial Performance - The company's revenue for Q3 2021 was ¥509,301,691.62, representing a 6.33% increase year-over-year, while the year-to-date revenue reached ¥1,460,919,478.78, up 17.44% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2021 was -¥65,197,855.35, a significant decline of 729.85% year-over-year, with a year-to-date net profit of -¥49,955,956.22, down 322.29%[3]. - The basic and diluted earnings per share for Q3 2021 were both -¥0.0866, reflecting a decrease of 732.12% compared to the same quarter last year[3]. - Total operating revenue for Q3 2021 reached ¥1,460,919,478.78, an increase from ¥1,243,975,860.94 in the previous period[42]. - Net profit for Q3 2021 was a loss of ¥32,739,792.19, compared to a profit of ¥43,432,188.41 in the same period last year[43]. - The company reported a basic and diluted earnings per share of -0.0663, down from 0.0298 in the previous year[44]. Cash Flow and Assets - The cash flow from operating activities for the year-to-date period was ¥135,051,996.20, an increase of 70.40%[3]. - The company’s cash inflow from sales of goods and services was ¥1,422,155,247.50, compared to ¥1,217,536,816.53 in the previous year[45]. - The ending cash and cash equivalents balance was $107,532,992.43, a decrease of 43% from $188,763,494.84 at the end of Q3 2020[47]. - The total cash outflow from operating activities was $1,407,217,164.16, up 9.8% from $1,281,910,454.14 in Q3 2020[47]. - The net cash flow from operating activities for Q3 2021 was $135,051,996.20, an increase of 70.6% compared to $79,257,584.73 in Q3 2020[47]. - The total assets at the end of the reporting period were ¥3,349,286,560.50, a decrease of 3.06% from the end of the previous year[3]. - Current assets totaled CNY 1,835,681,114.12, down from CNY 1,996,055,866.79 at the end of 2020, indicating a reduction in liquidity[38]. - The total liabilities decreased to ¥1,468,207,062.39 from ¥1,544,251,332.71 in the previous period[40]. - The company’s total assets decreased to ¥3,349,286,560.50 from ¥3,455,089,205.24[40]. Research and Development - Research and development expenses for the current period amounted to ¥44,358,000, an increase of 89.88% year-over-year, primarily due to increased R&D activities by subsidiaries[11]. - Research and development expenses increased to ¥44,358,033.15 from ¥23,360,722.76 year-over-year[42]. - The company plans to adjust its development strategy to focus on innovation-driven growth, enhancing competitiveness in cardiovascular, oral, digestive, gynecological, and narcotic fields, while exploring new biopharmaceutical areas[23]. - Duoduo Pharmaceutical has obtained a patent for a quality control evaluation method for a specific injection, which will enhance its intellectual property protection and promote technological innovation[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 98,608, with no preferred shareholders[15]. - The largest shareholder, Gome Holdings Group, holds 27.78% of shares, totaling 209,213,228 shares, with 124,101,400 shares pledged[15]. - As of the announcement date, Gome Holdings has pledged 124,101,400 shares, accounting for 59.32% of its holdings and 16.48% of the company's total share capital[20]. Regulatory Compliance and Approvals - The company has made significant progress in regulatory compliance and product approvals, which is expected to support future growth and market expansion[31][33]. - Subsidiary Duoduo Pharmaceutical has received the High-tech Enterprise Certificate, valid for three years, allowing it to enjoy a reduced corporate income tax rate of 15% during this period[24]. - Shandong Huasu has also obtained the High-tech Enterprise qualification, which allows it to benefit from a 15% corporate income tax rate for three years[27]. - Beijing Huasu is conducting clinical trials for a new traditional Chinese medicine for vascular dementia, with the first dose group already under observation[29]. Investment and Financing Activities - Cash received from borrowings for the current period was RMB 139.75 million, a decrease of 54.38% compared to the same period last year, mainly due to a reduction in bank borrowings[13]. - The cash inflow from financing activities was $139,750,000.00, down 54.8% from $309,385,000.00 in the same quarter last year[47]. - The net cash flow from financing activities was -$163,270,003.27, compared to -$33,521,750.56 in Q3 2020, indicating a significant increase in cash outflow[47]. Other Notable Events - The company signed a letter of intent for the transfer of full synthesis technology for morphine-related drugs with Sichuan University, committing to exclusive cooperation on related technologies and patents[21]. - The company has completed the cancellation of its fundraising account, with an interest balance of 51.55 yuan transferred to Hainan Huasu Pharmaceutical Marketing Co., Ltd. after deducting a service fee of 5 yuan, resulting in an actual amount of 46.55 yuan[22]. - The company did not undergo an audit for the Q3 2021 report[48]. - The report does not apply to the new leasing standards for the current year[48].

Financial Performance - The company's operating revenue for the reporting period was ¥951,617,787.16, representing a 24.40% increase compared to ¥764,975,280.04 in the same period last year[21]. - The net profit attributable to shareholders was ¥15,241,899.13, up 25.74% from ¥12,121,740.41 year-on-year[21]. - The net profit after deducting non-recurring gains and losses was ¥10,904,878.35, reflecting a 34.08% increase from ¥8,133,093.12 in the previous year[21]. - The basic earnings per share rose to ¥0.0202, a 25.47% increase from ¥0.0161 in the same period last year[21]. - The company achieved a consolidated revenue of 952 million yuan, representing a year-on-year growth of 24.40%[44]. - The net profit attributable to shareholders reached 15.24 million yuan, an increase of 25.74% compared to the previous year[44]. - The pharmaceutical and health products business generated a revenue of 668 million yuan, growing by 15.37% year-on-year, accounting for 70.17% of the total consolidated revenue[45]. Cash Flow and Assets - The net cash flow from operating activities decreased by 50.99% to ¥54,922,062.53, down from ¥112,060,303.68 in the same period last year[21]. - The total assets at the end of the reporting period were ¥3,386,905,834.74, a decrease of 1.97% from ¥3,455,089,205.24 at the end of the previous year[21]. - The net assets attributable to shareholders increased by 0.90% to ¥1,714,702,365.49 from ¥1,699,471,784.03 at the end of the previous year[21]. - The company's cash and cash equivalents decreased by 17.40% to a net increase of -¥90,350,713.27[60]. - The company's total financial assets amounted to 8,964,143.51, with no significant changes in measurement attributes during the reporting period[71]. Research and Development - The main business areas include biomedicine, personal care products, and elderly care services, with a focus on R&D and sales of various pharmaceutical forms[28]. - The company operates three R&D centers in Beijing, Shandong, and Heilongjiang, focusing on independent and collaborative research and development[35]. - The company is actively exploring the biopharmaceutical field and promoting the development of innovative drugs to enhance market competitiveness[42]. - The company has entered the registration process for several drugs, including Zhimu Saponin BⅡ and capsules, which are in Phase I clinical trials for treating vascular dementia[30]. - The company submitted the second supplementary response for Oxycodone Hydrochloride to the CDE on March 31, 2021, and is currently undergoing production process information approval[30]. Marketing and Sales - The company has established a comprehensive marketing system covering hospitals, retail pharmacies, and grassroots medical institutions, while also exploring online sales[35]. - The company has established a professional team for market promotion and access, enhancing brand influence and market penetration[37]. - The company is focusing on the integration of medical care and elderly care services, accelerating the development of the "Internet + Elderly Care" business model[38]. - The company launched two new products: "Probiotic Vitamin C Oral Tablets" and "Oral Ulcer Film," expanding its oral healthcare product line into three categories: prevention, treatment, and care[47]. - The company’s "Huasu Yuchuang" mouthwash won the "Most Popular Star Product Award" among pharmacies, highlighting its successful marketing strategy in the health product sector[47]. Legal and Compliance - The company reported a lawsuit involving a claim for 6.41 million yuan and interest of 410,000 yuan, totaling 6.41 million yuan, with an expected difficulty in recovering the amount[133]. - The company is pursuing a claim against Beijing Zhongyu Real Estate Development Co., Ltd. for a total of 6.581 million yuan, which includes a principal amount of 6 million yuan and interest[133]. - The company has ongoing litigation with Blue Ocean Company, seeking a compensation of approximately 39.71 million yuan, which is currently under execution[133]. - The company has recorded a provision for expected liabilities amounting to 28.05 million yuan related to ongoing litigation[134]. - The company is actively managing its legal risks and financial liabilities associated with ongoing lawsuits and claims[135]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities[107]. - The total chemical oxygen demand (COD) discharge was 1.82 tons for the half-year, with no exceedance of discharge standards[107]. - The company has established a comprehensive environmental management system, ensuring all pollutants are treated to meet the required standards, with no environmental issues reported during the reporting period[121]. - The company has passed the clean production report review in April 2021, demonstrating commitment to environmental sustainability[118]. - All pollutants from Beijing Huasu Pharmaceutical Co., Ltd. were within discharge standards during the reporting period[115]. Future Outlook - Future guidance suggests a targeted revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion strategies[88]. - The company plans to enhance its technology consulting services, aiming for a 15% increase in service-related revenue[88]. - The company is exploring opportunities in the healthcare and wellness sectors, with a focus on developing health-related products and services[88]. - The management has outlined a strategy to reduce operational losses by 10% in the upcoming quarters through cost optimization measures[88]. - The company is focusing on expanding its market presence through strategic partnerships and acquisitions in the healthcare sector[88].